ACTIVITY OF LM 2219 (DIFETHIALONE), A NEW ANTICOAGULANT RODENTICIDE, IN COMMENSAL RODENTS

ABSTRACT: Preliminary studies completed on commensal rodents with the new anticoagulant rodenticide difethialone showed very good efficacy, such that 25 ppm baits could be used effectively. New test results presented in this publication confirm the activity as shown under laboratory conditions in choice tests, which represent more severe conditions, as well as its effectiveness against rodents that are resistant and non-resistant to warfarin. In tests where the palatability was only fair the chemical activity resulted in excellent mortality. In a field test against a large population of Mus musculus the results proved very satisfactory. Difethialone is toxic to birds and fish. However, it seems to be better tolerated by dogs and pigs, animals that are frequently on the list of accidental poisonings. Difethialone is stored over a prolonged period in the liver but the risk to non-target species consuming rodents having ingested the compound does not seem to be high. For reasons attributed to the mode of action, difethialone must be handled with precautions as other anticoagulants for which Vitamin Kj is the antidote. In the event of an accidental poisoning, an antidotal therapy plan is proposed. The lower levels of active ingredient in finished baits (25 ppm) should pose a low risk to non-target species.

STATUS OF BROMETHALIN OUTSIDE THE UNITED STATES

ABSTRACT: Bromethalin has been extensively researched over the past decade in the United States, Switzerland, England, Denmark, and France. United States EPA registrations were received in 1982 and commercial pelleted formulations containing 0.01% bromethalin were developed and introduced in the USA by Ralston Purina (ASSAULT1*) in 1985 and Velsicol (VENGEANCE1*) in 1986. Ciba-Geigy is currently developing new formulations under the tradename DORATIDR for use outside the United States. Bromethalin acute toxicity and 14-day subchronic studies are reviewed and data from recently completed 90-day subchronic studies required for registration outside the US are presented. Pharmacodynamic studies have shown that bromethalin acts as an uncoupler of oxidative phosphorylation, thus interrupting the vital production of ATP necessary to maintain essential metabolic functions. Laboratory and field trial data are presented from Switzerland, France, England, and Denmark that indicate the effectiveness of new bromethalin formulations against anticoagulant resistant and susceptible rodents. A comparative rodenticide pen testing system is described from which test results confirm bromethalin's quick action and feed consumption efficiency when compared to second-generation anticoagulants.